𝔖 Bobbio Scriptorium
✦   LIBER   ✦

CA 19-9 and CA 50 in Benign and malignant pancreatic and biliary diseases

✍ Scribed by Michela Paganuzzi; Marina Onetto; Paola Marroni; Daniela Barone; Massimo Conio; Hugo Aste; Vittorio Pugliese

Publisher
John Wiley and Sons
Year
1988
Tongue
English
Weight
555 KB
Volume
61
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis

Serum concentrations of the CA 19-9 and CA 50 antigens were determined in 129 patients with malignant and benign biliary and pancreatic diseases. Values for the two markers were highly correlated (P < 0.001). The concentrations of CA 19-9 and CA 50 were positive in 84.6% and 80.7% of patients with pancreatic cancer, respectively. The overall specificity of CA 19-9 (92.4%) was slightly higher than that of CA 50 (88.5%). The sensitivity of CA 50 (91.3%) was greater than that of CA 19-9 (73.9%) in patients with diseases of the biliary tract. Elevated concentrations of CA 19-9 (12.9%) and CA 50 (35.2%) were also found in a number of cases with benign disease, especially in patients with obstructive jaundice. These data suggest that both CA 19-9 and CA 50 can be useful markers of pancreatic cancer in nonjaundiced patients. The joint use of the two markers does not yield a better diagnostic resolution than the use of either one alone.

πŸ“œ SIMILAR VOLUMES

CEA, CA 19-9, and CA 125 in the differen
CEA, CA 19-9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice
✍ NΓΌvit Duraker; Semih Hot; YΓΌcel Polat; Anil HΓΆbek; Nur GenΓ§ler; Nuray Urhan πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 103 KB

## Abstract ## Background and Objectives In this study, the value of the serum tumor markers carcinoembryonic antigen (CEA), CA 19‐9, and CA 125 was assessed in the differential diagnosis of benign and malignant pancreatic diseases with and without obstructive jaundice. ## Methods Serum levels o

CA 19-9 and pancreatic adenocarcinoma
CA 19-9 and pancreatic adenocarcinoma
✍ Farouk Safi; Hans G. Beger; Reinhard Bittner; Markus BΓΌchler; Wolfgang Krautzber πŸ“‚ Article πŸ“… 1986 πŸ› John Wiley and Sons 🌐 English βš– 327 KB

The diagnostic place value of CA 19-9, a tumor-associated antigen, was tested in 611 patients. This group of patients included 273 patients who suffered from a malignant disease (48 patients with pancreatic carcinomas and 225 patients with extrapancreatic malignant growths) and 338 patients with ben

Serum ca 50 as a tumor marker in pancrea
Serum ca 50 as a tumor marker in pancreatic cancer: A comparison with CA 19-9
✍ Caj Haglund; Pentti Kuusela; Hannu Jalanko; Peter J. Roberts πŸ“‚ Article πŸ“… 1987 πŸ› John Wiley and Sons 🌐 French βš– 459 KB

CA 50 is a new tumor marker based on a monoclonal anti-carcinoid tumor, 2 cystadenocarcinomas, 2 anaplastic carcibody (MAb) against a human colorectal carcinoma cell line.The nomas, 15 poorly differentiated and 39 well-to moderately-CA 50 antigen is similar, but not identical, to the tumor different

Values of CA 19-9 in the serum, pure pan
Values of CA 19-9 in the serum, pure pancreatic juice, and aspirated pancreatic material in the diagnosis of malignant pancreatic tumor
✍ Masaharu Tatsuta; Hisako Yamamura; Hiroyasu Iishi; Makoto Ichii; Sanai Noguchi; πŸ“‚ Article πŸ“… 1985 πŸ› John Wiley and Sons 🌐 English βš– 601 KB

The diagnostic accuracy of the measurement of CA 19-9 in the serum, pure pancreatic juice, and aspirated pancreatic fluid in the diagnosis of pancreatic tumors was assessed in 32 patients with ndigmnt pancreatic tumors and 19 patients with pancreatitis. Pure pancreatic juice was collected from the p